Literature DB >> 11933181

Radiotherapy for carcinoma in situ of the true vocal cords.

Allie Garcia-Serra1, Russell W Hinerman, Robert J Amdur, Christopher G Morris, William M Mendenhall.   

Abstract

PURPOSE: To report long-term rates of tumor control after radiotherapy (RT) for carcinoma in situ (CIS) of the true vocal cords (TVC). A comprehensive literature review was performed, and outcomes with other modalities of treatment for CIS of the TVC were compared. METHODS AND MATERIALS: Thirty patients with CIS of the TVC were treated between July 1967 and May 1998 with curative intent using megavoltage RT. Most patients (28 of 30) were treated with cobalt-60 through small (usually 5 x 5 cm) fields. Median RT dose was 56.25 Gy (range, 56.25-75 Gy; mean dose, 59.15 Gy) at 2.25 Gy per fraction. One patient was treated for a synchronous head and neck primary malignancy with large fields to a total dose of 75 Gy at 1.8 Gy per fraction. Approximately two thirds of the patients (19 of 30) were referred for RT because of recurrence after at least one stripping procedure.
RESULTS: With a mean follow-up of 7.1 years (range, 2-17 years), the 5-year rates of local control, local control with larynx preservation, and ultimate local control (including salvage surgery) were the following: 88%, 88%, and 100%, respectively. Invasive squamous cell carcinoma developed in three (10%) of the patients. Time to failure was 14 months, 34 months, and 48 months, respectively. All three patients were surgically salvaged with a total laryngectomy. Cause-specific survival at 5 years was 100%. There were no late complications.
CONCLUSIONS: RT to approximately 60 Gy at 2.25 Gy per fraction using small (5 x 5 cm) fields produces excellent results with CIS of the TVC. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11933181     DOI: 10.1002/hed.10071

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Hypofractionation vs. conventional radiotherapy fractionation in the conservative treatment of T1 glottic cancer: a prospective cohort study.

Authors:  B G Salas-Salas; D J Domínguez-Nuez; R Cabrera; L Ferrera-Alayón; M Lloret; P C Lara
Journal:  Clin Transl Oncol       Date:  2019-06-01       Impact factor: 3.405

Review 2.  Management of laryngeal dysplasia: a review.

Authors:  Maziar Sadri; Jeremy McMahon; Andrew Parker
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-07-06       Impact factor: 2.503

3.  Patterns of Care for Patients With Early-Stage Glottic Cancer Undergoing Definitive Radiation Therapy: A National Cancer Database Analysis.

Authors:  William A Stokes; Diana Abbott; Andy Phan; David Raben; Ryan M Lanning; Sana D Karam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-06       Impact factor: 7.038

4.  Carcinoma in situ of true vocal cord in a nonsmoker adolescent female.

Authors:  Dodul Mondal; Sayan Kundu; Subrata Chattopadhyay; Sumitava De; A Ghosh Dastidar; Amitabha Roy
Journal:  Indian J Med Paediatr Oncol       Date:  2009-01

5.  Photodynamic therapy for head and neck dysplasia and cancer.

Authors:  Nestor R Rigual; Krishnakumar Thankappan; Michele Cooper; Maureen A Sullivan; Thomas Dougherty; Saurin R Popat; Thom R Loree; Merrill A Biel; Barbara Henderson
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-08

6.  Early Glottic Squamous Cell Carcinoma in a 16-Year-Old: Case Report, Review of the Literature and Pediatric Head and Neck Radiotherapy Guidelines.

Authors:  Rajesh Balakrishnan; Qamruzzaman Chowdhury; Mohammed Astefchar Hussain; Muhammad Masudul Hassan Arup; Nizamul Haque; Fariah Sharmeen; Arunangshu Das; Bidoura Naznin
Journal:  Case Rep Oncol       Date:  2015-08-20

7.  Outcome of Early-Stage Glottic Laryngeal Carcinoma Patients Treated with Radical Radiotherapy Using Different Techniques.

Authors:  Oguz Cetinayak; Ersoy Dogan; Ahmet Kuru; Nesrin Akturk; Barbaros Aydin; Cenk Umay; Ilhami Er; Fadime Akman
Journal:  J Oncol       Date:  2019-11-06       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.